Literature DB >> 23473944

Can population pharmacokinetic modelling guide vancomycin dosing during continuous renal replacement therapy in critically ill patients?

Andrew A Udy1, Cecilia Covajes, Fabio Silvio Taccone, Frédérique Jacobs, Jean-Louis Vincent, Jeffrey Lipman, Jason A Roberts.   

Abstract

Treatment of resistant bacteria such as meticillin-resistant Staphylococcus aureus (MRSA) relies on achieving adequate antibiotic concentrations at the site of infection. Strategies to attain such targets in septic critically ill patients receiving renal replacement therapy (RRT) are uncommon but could be useful for increasing the likelihood of therapeutic dosing. The aim of this study was to conduct a population pharmacokinetic (PK) analysis in septic patients undergoing continuous RRT and to determine which parameters were associated with inadequate vancomycin concentrations. In total, 81 patients with 199 blood samples were included in the study. All patients received vancomycin dosing according to the local protocol, which included a weight-based loading dose followed by continuous infusion. The vancomycin concentration-time points were adequately described with a one-compartment model with zero order input. The median population PK estimate for vancomycin clearance (CL) was 2.9 L/h [interquartile range (IQR) 2.4-3.4 L/h] and for volume of distribution (Vd) was 0.8 L/kg (IQR 0.6-1.1 L/kg). The goodness-of-fit plots for the model were adequate. When covariates were tested, none were found to adequately explain changing vancomycin CL or Vd in the population PK model. In particular, the lack of correlation between CL and RRT settings was likely due to the multiple confounders known to influence antibiotic prescription in this setting. These data provide a cautionary tale of the challenges of describing pharmacokinetics in critically ill patients receiving RRT and highlights the need for a detailed, prospective, multicentre study to better inform dosing practice.
Copyright © 2013 Elsevier B.V. and the International Society of Chemotherapy. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23473944     DOI: 10.1016/j.ijantimicag.2013.01.018

Source DB:  PubMed          Journal:  Int J Antimicrob Agents        ISSN: 0924-8579            Impact factor:   5.283


  9 in total

Review 1.  Clinical implications of antibiotic pharmacokinetic principles in the critically ill.

Authors:  Andrew A Udy; Jason A Roberts; Jeffrey Lipman
Journal:  Intensive Care Med       Date:  2013-09-18       Impact factor: 17.440

Review 2.  Optimizing the Clinical Use of Vancomycin.

Authors:  Rocío Álvarez; Luis E López Cortés; José Molina; José M Cisneros; Jerónimo Pachón
Journal:  Antimicrob Agents Chemother       Date:  2016-04-22       Impact factor: 5.191

3.  External Evaluation of Population Pharmacokinetic Models of Vancomycin in Large Cohorts of Intensive Care Unit Patients.

Authors:  Tingjie Guo; Reinier M van Hest; Luca F Roggeveen; Lucas M Fleuren; Patrick J Thoral; Rob J Bosman; Peter H J van der Voort; Armand R J Girbes; Ron A A Mathot; Paul W G Elbers
Journal:  Antimicrob Agents Chemother       Date:  2019-04-25       Impact factor: 5.191

Review 4.  An Update on Population Pharmacokinetic Analyses of Vancomycin, Part I: In Adults.

Authors:  Abdullah Aljutayli; Amélie Marsot; Fahima Nekka
Journal:  Clin Pharmacokinet       Date:  2020-06       Impact factor: 6.447

5.  Competence Mining of Vancomycin (VAN) in the Management of Infections Due to Bacterial Strains With High VAN Minimum Inhibitory Concentrations (MICs): A Novel Dosing Strategy Based on Pharmacokinetic/Pharmacodynamic Modeling.

Authors:  Xiangqing Song; Meizi Zeng; Yi Wu; Yong Pan
Journal:  Front Microbiol       Date:  2021-04-22       Impact factor: 5.640

6.  Factors affecting serum concentration of vancomycin in critically ill oliguric pediatric patients receiving continuous venovenous hemodiafiltration.

Authors:  Bongjin Lee; Soo Jung Kim; June Dong Park; Jiun Park; Ae Hee Jung; Sun Hoi Jung; Yu Hyeon Choi; Hee Gyung Kang; Il Soo Ha; Hae Il Cheong
Journal:  PLoS One       Date:  2018-06-21       Impact factor: 3.240

7.  Exploring population pharmacokinetic models in patients treated with vancomycin during continuous venovenous haemodiafiltration (CVVHDF).

Authors:  Marcus Kirwan; Reema Munshi; Hannah O'Keeffe; Conor Judge; Mary Coyle; Evelyn Deasy; Yvelynne P Kelly; Peter J Lavin; Maria Donnelly; Deirdre M D'Arcy
Journal:  Crit Care       Date:  2021-12-20       Impact factor: 9.097

8.  Comparison of area under the curve for vancomycin from one- and two-compartment models using sparse data.

Authors:  Nyein Hsu Maung; Janthima Methaneethorn; Thitima Wattanavijitkul; Tatta Sriboonruang
Journal:  Eur J Hosp Pharm       Date:  2021-07-20

9.  Does contemporary vancomycin dosing achieve therapeutic targets in a heterogeneous clinical cohort of critically ill patients? Data from the multinational DALI study.

Authors:  Stijn Blot; Despoina Koulenti; Murat Akova; Matteo Bassetti; Jan J De Waele; George Dimopoulos; Kirsi-Maija Kaukonen; Claude Martin; Philippe Montravers; Jordi Rello; Andrew Rhodes; Therese Starr; Steven C Wallis; Jeffrey Lipman; Jason A Roberts
Journal:  Crit Care       Date:  2014-05-15       Impact factor: 9.097

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.